The FDA has approved a new drug application for Avaclyr, Fera Pharmaceuticals’ herpetic keratitis treatment, according to a press release.
Avaclyr (acyclovir ophthalmic ointment 3%), a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated to treat dendritic ulcers in patients with HSV-1 and HSV-2, the release said.
In addition, Avaclyr was granted orphan drug exclusivity.
“Avaclyr approval is a major milestone for the company,” Frank DellaFera, Fera’s founder and president, said in the release. “Working closely with the eye care community we
Uncategorized